GRI Bio Inc expected to post a loss of $1.19 a share - Earnings Preview

GRI Bio

10/08/2026 15:14

GRI Bio Inc GRI.OQ GRI.O is expected to  show no change in quarterly revenue when it reports  results on August 12 (estimated) for the period ending June 30 2026

​LSEG's mean analyst estimate for GRI Bio Inc is for a loss of $1.19 per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for GRI Bio Inc is $156.00, about 10,512.2% above its last closing price of $1.47
This summary was machine generated August 10 at 14:14 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)